Tag : RRMS

Latest News

FDA Clears Ozanimod (Zeposia) for MS; COVID-19 Delays Launch

Newsemia
Ozanimod is the first oral, once-daily sphingosine-1-phosphate receptor modulator approved for adults with relapsing forms of multiple sclerosis. Source link...
Neurology

MESEMS: No Reduction in MS Lesions With Stem Cell Therapy

Newsemia
Although the primary outcome of a multinational phase 2 study was negative, researchers said promising secondary findings support the use of mesenchymal stem cells in...
Pharma / Biotech

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Newsemia
Related Articles Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinflamm. 2019 Sep;6(5): Authors: Ghezzi A, Comi G, Grimaldi LM, Moiola...
Neurology

ORACLE-MS: Cladribine Effective in MS Subgroups

Newsemia
The recently approved disease-modifying therapy is expected to find a niche for patients with multiple sclerosis who fail other agents. Medscape Medical News Source link...
Neurology

PRAC Restricts Use of Alemtuzumab for MS Pending Ongoing Review

Newsemia
The EMA committee recommends updating the product information to note the potential for acute immune-mediated conditions, stroke, cervicocephalic arterial dissection, and severe neutropenia. News Alerts...
Neurology

Pace of Multiple Sclerosis Progression May Be Slowing

Newsemia
The risk for reaching specific disability milestones in patients with multiple sclerosis has decreased over the past decade, a large cohort study from Sweden suggests....
Neurology

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Newsemia
Related Articles Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS)...
Neurology

MS Linked to Alterations in Bile Acid Metabolism

Newsemia
Abnormalities of these cholesterol metabolites in both children and adults with MS, along with encouraging preclinical findings, have spurred a clinical trial to assess supplementation...
Neurology

Novel Anti-B-Cell Therapy Looks Promising in MS

Newsemia
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study....
Neurology

'Burning Debate' on McDonald Diagnostic Criteria in MS

Newsemia
New McDonald diagnostic criteria for multiple sclerosis were the focus of a debate here at the ECTRIMS 2018 congress that spilled over onto Twitter. Medscape...
Neurology

Years of Thyroid Monitoring Needed After MS Drug Alemtuzumab

Newsemia
New study shows fluctuating patterns of thyroid dysfunction and later onset than previously seen associated with the MS drug alemtuzumab, suggesting the need for ongoing...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy